Merck & Co. (MRK) : Kistler-tiffany Companies scooped up 628 additional shares in Merck & Co. during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 6, 2016. The investment management firm now holds a total of 41,779 shares of Merck & Co. which is valued at $2,479,584.Merck & Co. makes up approximately 1.26% of Kistler-tiffany Companies’s portfolio.
Other Hedge Funds, Including , Laurel Wealth Advisors reduced its stake in MRK by selling 637 shares or 3.42% in the most recent quarter. The Hedge Fund company now holds 17,981 shares of MRK which is valued at $1,067,172. Merck & Co. makes up approx 0.52% of Laurel Wealth Advisors’s portfolio. Indiana Trust Investment Management Co added MRK to its portfolio by purchasing 3,813 company shares during the most recent quarter which is valued at $221,154. Merck & Co. makes up approx 0.12% of Indiana Trust Investment Management Co’s portfolio. Pensionfund Dsm Netherlands added MRK to its portfolio by purchasing 145,500 company shares during the most recent quarter which is valued at $8,439,000. Merck & Co. makes up approx 1.13% of Pensionfund Dsm Netherlands’s portfolio.Needelman Asset Management Inc reduced its stake in MRK by selling 25 shares or 0.18% in the most recent quarter. The Hedge Fund company now holds 13,755 shares of MRK which is valued at $797,790. Merck & Co. makes up approx 2.29% of Needelman Asset Management Inc’s portfolio.Cullinan Associates Inc boosted its stake in MRK in the latest quarter, The investment management firm added 4,050 additional shares and now holds a total of 231,161 shares of Merck & Co. which is valued at $13,393,468. Merck & Co. makes up approx 1.09% of Cullinan Associates Inc’s portfolio.
Merck & Co. closed down -0.01 points or -0.02% at $59.34 with 73,36,741 shares getting traded on Monday. Post opening the session at $59.26, the shares hit an intraday low of $59.2 and an intraday high of $59.75 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Merck & Co. reported $0.89 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on May 5, 2016. Analyst had a consensus of $0.85. The company had revenue of $9312.00 million for the quarter, compared to analysts expectations of $9445.10 million. The company’s revenue was down -1.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.85 EPS.
Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Companys Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Companys animal health products are sold to veterinarians distributors and animal producers.